156±18 mmHg/85±11 mmHg, serum creatinine 150±53 mmol/l (1.7±0.6 mg/dl ), creatinine clearance Background. Diabetic nephropathy is the most common cause of end-stage renal disease in the 66±34 ml/min and 24 h urine protein 4.0±3.5 g/day. developed world. Angiotensin-converting enzyme Keywords: angiotensin II receptor antagonist; diabetic inhibitors have been demonstrated to be renoprotective nephropathy; renoprotection; type II diabetes in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin-angiotensin system in type II Introduction diabetic patients is not defined. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic nephropathy is the most common end-stage Diabetic Nephropathy Trial (IDNT ), studying the renal disease ( ESRD) diagnosis in most of the effect of the angiotensin II receptor antagonist irbesar-developed world, and is responsible for 43% of all new tan on progression of renal disease and mortality in patients requiring renal replacement therapy in the type II diabetic patients with overt nephropathy and USA [1]. The incidence rate of diabetic ESRD is hypertension. Here we report the study design and increasing by 10% a year [1]. This near epidemic baseline patient characteristics.
Enrolment of 1650 patients will occur in~225 active centres.
cause mortality as part of a composite primary endRandomization began in March 1996 and was expected to point. Irbesartan's effects on these end-points will be end in March 1998. Due to a slow early enrolment rate, the compared with two other treatment arms: a placebo DSMC decided to extend enrolment until December 1998 or control group and a group receiving the calcium chan-until 1650 patients were randomized, whichever occurred nel blocker (CCB) amlodipine as the primary antihy-first. The average length of patient follow-up is expected to pertensive agent. Every effort will be made to attain be~36 months. equivalence of blood pressure control in the three arms of the trial by utilizing other antihypertensive agents Statistical considerations as needed (with the exclusion of ACEIs, AIIRAs or CCBs). The inclusion of the calcium channel blocker Hypotheses and end-points. The primary and secondary hypoarm may help to determine specificity of any renopro-theses and end-points/outcome measures are presented in tection afforded by any of these regimens. Herein we Table 2 . report the basic study protocol as well as a number of Sample size. The sample size estimate for this trial was determined to test the hypothesis that the time to reach the baseline characteristics of the study population.
primary composite end-point in irbesartan-treated type II diabetic patients with hypertension and diabetic nephropathy Subjects and methods will be greater than that for placebo-treated type II diabetic patients with hypertension and diabetic nephropathy. The projected rates of progression of renal failure and mortality
Collaborative Study Group structure
were derived from reports in type II diabetics and the captopril trial in type I diabetics with diabetic nephropathy The Collaborative Study Group (CSG, see Appendix for [5] , utilizing suggestions that progression of renal disease in complete list of structure and members) consists of~208 type II patients is similar to that observed in type I patients collaborating clinics, three Clinical Coordinating Centres with diabetic nephropathy [3] . (CCCs) and a Biostatistical Coordinating Centre (BCC ).
The sample size calculations were based on formulas The CCCs oversee the proper execution of the study protocol discussed in Lachin and Foulkes [10] . For purposes of sample and the CCC in the USA provides central laboratory analysis size calculations, the total duration of this trial was expected of specific parameters critical to study outcomes. The BCC to be 4 years, with a 2 year enrolment period and a minimum is responsible for data analysis as well as the statistical design 2 year follow-up after the last patient is enrolled for an of the trial. The BCC also prepares the safety and efficacy average follow-up of 3 years. The projected 3 year cumulative reports for the Data and Safety Monitoring Committee total incidence rate of the composite end-point is 36% in the (DSMC ) which includes experts in the fields of nephrology, placebo group and consists of a 26% incidence of doubling diabetes, statistics and ethics who are not associated with of baseline serum creatinine, ESRD and non-cardiovascular any of the collaborating clinics. death, and a 10% incidence of cardiovascular death. An Executive Committee is made up of a rotating member-
The sample size calculations assume a uniform (constant) ship of selected collaborating investigators and oversees the enrolment rate and that within both treatment groups, the design of the trial and the execution of study protocol. A distribution of the times until first occurrence of the composClinical Review Committee (CRC ), consisting of selected ite end-point is exponential with a constant hazard (risk) collaborating investigators, monitors adherence to the study rate. To ensure that a risk reduction of 26% can be detected protocol and reviews the medical management of all patients.
with 0.90 power with a log rank test at the two-sided alpha An Outcome Confirmation and Classification Committee level of 0.05, it would be necessary to randomize 520 patients (OCCC ) consisting of selected collaborating investigators per arm, allowing for a total of 316 events in the irbesartan provides classification of study outcomes and stop points.
and placebo treatment arms. To account for rescue therapy The DSMC together with the principal investigators from with an ACEI or an AIIRA for treatment of complications the USA CCC and BCC monitors the results of the trial in associated with non-fatal cardiac events, a total of 550 an unblinded fashion with respect to risks and benefits to patients will be randomized to each group. the patients. Interim statistical analyses are reviewed at least yearly in order for the committee to advise continuation or early stopping of the trial on the basis of current results.
Patient population
This randomized, double-blind, placebo-controlled trial Study design will be conducted worldwide. Qualifying men and women with type II diabetes mellitus, hypertension, proteinuria This trial is an international, prospective, randomized, of Á900 mg/24 h, and serum creatinine levels 90-265 double-blind, placebo-controlled trial in hypertensive mmol/l (1.0-3.0 mg/dl ) in women and 110-265 mmol/l patients with diabetic nephropathy due to type II diabetes (1.2-3.0 mg/dl ) in men will be randomized to one of three mellitus. Patients will be randomized into one of three arms: treatments: irbesartan, amlodipine or placebo. The efficacy (i) angiotensin II receptor antagonist; (ii) calcium channel analyses will be based on data from all randomized patients blocker; and (iii) placebo control, with each group receiving at all worldwide sites. All patients who receive at least one additional antihypertensive agents (with the exclusion of dose of study drug will be included in the safety analyses. ACEIs, AIIRA or CCB) to achieve equivalent blood pressure values in each of the three groups. The study protocol and patient consent form are reviewed and approved by each Baseline comparability individual clinic's Institutional Review Board for Human Investigation. All patients entered into the trial signed an Demographic (age, gender, ethnicity, etc.) , disease status and other baseline characteristics will be summarized by treatinformed consent and were eligible based on the eligibility and exclusion criteria prior to randomization (Table 1) . ment group and for all randomized patients. x2 (qualitative The influence of baseline prognostic factors upon the chosen based upon evidence of any imbalances that may F. revascularization (cardiac, carotid, peripheral vascular) exist between the treatment groups. If, for example, irbesartan achieves a clinically significant reduction compared with placebo in blood pressure, then the relevant variables will be data) or analysis of variance (quantitative data) will be used added to the Cox regression model as time-dependent covarito compare the treatment groups. Any imbalances among ates to examine the potential confounding upon the mortalthe treatment groups for variables which are strongly ity/morbidity results. suspected of having a bearing on progression of renal disease or mortality (e.g. age, ethnicity, lipids) will be investigated to assess their effects on the efficacy comparison.
Study plan
The trial consists of screening, enrolment, titration and Efficacy analysis maintenance periods. Screening period. Patients will be screened for inclusion and The primary analysis will be intention to treat. The primary comparison will be between irbesartan and placebo. The exclusion criteria. Serum creatinine and 24 h urine for protein and creatinine clearance are obtained. A 'baseline' seated time-dependent outcome measures include the primary composite end-point of doubling of baseline serum creatinine, systolic and diastolic blood pressure is determined from which a patient's blood pressure control 'goal' is determined ESRD or all-cause mortality, each of the individual components of the primary end-point, the combination of ESRD or (see 'Titration period'). ACEIs and AIIRAs must be discontinued for at least 10 days prior to collection of the first all-cause mortality, the combination of ESRD or doubling of serum creatinine and the secondary and tertiary composite 24 h urine.
Enrolment period. A second serum creatinine is obtained; the end-points of fatal or non-fatal cardiovascular events. All time-dependent outcome measures will be summarized by difference between the screening and enrolment period serum creatinines must not be greater than 25% to ensure stable using the Kaplan-Meier [11] procedure to estimate a survival curve for each treatment group. For the primary and second-renal function, in order for the patient to qualify for ran-domization. If calcium channel blockers were continued the serum creatinine is still elevated by 50% and at least 88 mmol/l (1.0 mg/dl ), the coded medication is stopped. If during the screening and enrolment periods, they must be stopped prior to randomization. the serum creatinine decreases (to a value below the 50% and at least 88 mmol/l (1.0 mg/dl ) increase), the subject will Titration period. Patients are randomized 15151 to regimens of irbesartan, amlodipine or placebo. The overall goal is to be rechallenged with a lower dose ( level ) of coded medication. If after reinstituting the coded medication, the serum maximize the dose of coded study drug and to minimize the use of other antihypertensive agents. To allow for titration creatinine again begins to rise, the investigator shall declare a stop point due to the subject being unable to tolerate the to the highest tolerated dose of coded study drug, discontinuation of other antihypertensive medications may be required coded medication. Although off study drug, the subject would continue to be seen at regularly scheduled study visits. between randomization and week 4. The doses of study drug administered initially are irbesartan 75 mg, amlodipine Doubling of serum creatinine. The primary study end-point is defined as a doubling of the baseline serum creatinine, 2.5 mg or placebo once daily (Level I ). At the end of week 2, the dose of study drug will be increased to irbesartan confirmed by the central laboratory. To verify that the doubling of the serum creatinine is due to the progression of 150 mg, amlodipine 5 mg or placebo once daily in all patients as tolerated (Level II regimen) and further increased to diabetic nephropathy, the investigator must determine whether the subject is taking medications which alter serum irbesartan 300 mg, amlodipine 10 mg or placebo at the end of week 4 in all patients as tolerated (Level III regimen).
creatinine or if any of the potentially reversible conditions listed in 'Early rise in serum creatinine' (above) are present. The target blood pressure control goal for the majority of patients is a systolic blood pressure of <135 mmHg, and for If any of these conditions are present, the investigator should take corrective measures and recheck the serum creatinine. all patients a diastolic blood pressure of <85 mmHg. (i) If the baseline seated systolic blood pressure (SeSBP) is If the subject's serum creatinine is still equal to or greater than twice the baseline value, the patient has reached a >145 mmHg at the first screening visit, the target SeSBP goal is a decrease of at least 10 mmHg. (ii) The maximum creatinine doubling stop point. The coded study medication is discontinued; however, the subject continues in the routine allowable target SeSBP goal is 160 mmHg. All patients must return at the end of 8 weeks to confirm that target blood follow-up visit schedule until dialysis, transplantation, death or end of trial. pressure goals have been reached. Maintenance period. Patients will be seen every 3 months End-stage renal disease. ESRD is defined as the permanent need for dialysis (as deemed necessary by the investigator), beginning at the end of month 3. Serum chemistries are obtained and blood pressure is taken. If at any scheduled renal transplantation or a serum creatinine Á530 mmol/l (6.0 mg/dl ) repeated and confirmed by the central laboratory. visit the blood pressure is above a patient's goal, a change in medication is made and patients are seen within 7 days. Patients reaching an ESRD stop point will have the coded medication discontinued and no further visits are required This is repeated until the patient reaches blood pressure goal. Twenty-four hour urine collections for protein and creatinine although vital status is monitored until the end of the trial. clearance are obtained every 6 months. All randomized patients who discontinue the study drug for any reason other than death will be followed for the entire duration of the Results trial; patients who undergo renal transplantation or dialysis will be followed for vital status only. Information about hospitalization for any cause is collected at each visit.
Baseline characteristics
The baseline patient characteristics (n=1640) are presented in Tables 3 and 4 excretion is 4.0 g/day. Almost three-quarters of the Hyperkalaemia. Subjects will have their serum potassium patients are white, reflecting almost one half of the measured at all scheduled follow-up visits. Values >6.0 study patients being recruited from clinics in Europe. mEq/l require corrective measures and the possible discontin-The international breakdown of patient enrolment is uation of study drug. Every attempt is made to keep patients provided in Figure 1 . with the baseline creatinine clearance and the baseline Early rise in serum creatinine. Subjects will have their serum 24 h urinary protein excretion using Spearman correlacreatinine measured by the regional study laboratory at all tions for ordinal scale variables and Kendall Tau-B scheduled follow-up visits. If during the first 8 weeks follow-correlations for categorical variables. Those comparing randomization the serum creatinine rises by 50% and at isons with a P-value <0.05 are presented in Table 5 . least 88 mmol/l (1.0 mg/dl ), the subject is defined as having Although there are a number of statistically significant an early rise in serum creatinine event. The subject will be associations, the r values in many of these comparisons evaluated for (i) medications which alter serum creatinine, are extremely low; the number of observations (n= (ii) plasma volume depletion, (iii) infected urine, (iv) 1640) allowing even weak associations to be statisticobstructive uropathy and (v) decreased cardiac output.
The clinic director should take corrective measures and, if ally significant. Although the correlations are all weak, renoprotective and proteinuria lowering properties similar to ACEIs in many models. There are reasons to believe that the renoprotection afforded by AIIRAs each of the diabetic complications, e.g. retinopathy, may be superior or inferior to that of ACEIs. ACEIs gastropathy, etc., are all negatively correlated prevent the enzymatic breakdown of bradykinin, while with creatinine clearance (the risk of a non-renal AIIRAs have no effect on this vasodilatory hormone. complication increases with decreases in creatinine The preservation of bradykinin and its effect on the clearance). This seems to indicate simply that one efferent arteriole may be responsible for some of the major complication (nephropathy) is associated with salutary effects of angiotensin-converting enzyme the development of other complications and may reflect inhibition, although the effect of bradykinin on renal overall severity of disease. The strongest correlations haemodynamics appears to be species dependent are those that are the easiest explained, e.g. serum [14] [15] [16] . Since renoprotection with ACEIs is the gold albumin, total protein and lipid levels to 24 h urinary standard, we would have preferred to have a fourth protein excretion.
treatment arm utilizing such an agent. This, however, would have required an increase in trial size from 1650 to 2100 patients in order to maintain the same study Discussion power; the patient recruitment and cost of which did not seem feasable. A major factor in the success of any nephropathy In 1993, the Collaborative Study Group's study of the effect of the ACEI, captopril, was reported in patients trial rests in choosing a population of patients in whom renal disease is progressive so that the potential salutwith type I diabetic nephropathy [5] . This was a study of the time to event of a doubling of serum creatinine ary effects of a treatment can be demonstrated. We felt that this required inclusion criteria that selected of the trial, an increase in that patient's serum creatinine will reflect a deterioration in GFR. Since creatinine patients that had already progressed to a degree, and therefore chose a minimum of 900 mg of daily urinary secretion increases as GFR falls, increases in serum creatinine may actually underestimate a reduction in protein excretion and a serum creatinine that reflected early renal insufficiency. In fact, the average patient GFR, and GFR may fall without a significant change in serum creatinine. In this regard, a doubling of serum enrolled in this study is excreting 4 g of daily urinary protein and has lost half of their renal function. Thus, creatinine should represent at least a 50% reduction in GFR. Indeed this is what we found in the type I we feel that this represents a population of patients in whom a downhill course in renal function is predicted captopril trial where we measured GFR through the urinary clearance of [125I ]iothalamate [5] . It is for and who are, therefore, well suited for an interventional study.
these reasons that we believe that an end-point based on a patient's doubling of serum creatinine is a more We have chosen a renal end-point based on serum creatinine as opposed to a method of isotope clearance practical measure of deterioration in renal function than one based on relatively infrequently obtained that estimates glomerular filtration rate (GFR). Although the latter are more accurate measures of GFR measurements.
There is increasing evidence that proteinuria, in renal function, and change in GFR over time (slopes) can be generated for each patient and thus compared itself, plays a pathogenic role in the progression of renal failure. In this regard, agents that lower probetween treatment groups, these tests need to be performed frequently if reliable curves are to be generated. teinuria may be more likely to preserve renal function than those that do not lower, or indeed increase, This is especially true for many patients in whom little deterioration in GFR may be seen over the course of proteinuria. Thus, the effect of an antihypertensive agent on the level of proteinuria may be a surrogate a study. Frequent use of GFR measurements is both cumbersome and expensive. Serum creatinine values, for whether or not an agent offers renoprotection.
CCBs may either increase or decrease proteinuria on the other hand, are easy to perform, quite reproducible and inexpensive. Although the same serum creati-depending on the class being studied [17] [18] [19] .
Amlodipine is a dihydropyridine CCB and has been nine value may represent different GFR values in different patients, unless creatinine production in a shown to increase proteinuria in some models. This CCB was chosen for use in this trial because it was given patient increases considerably during the course Table 5 . Correlations of baseline creatinine clearance (C Cr ) and 24 h be overshadowed by the risk lowering effects of the urinary protein excretion to other baseline characteristics relatively aggressive blood pressure control that we are striving for. Our trial is powered for primary end- 1958; 53: 457-481 (actual blood pressures attained during the study were 12. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 187-202 lower at 144/82 mmHg vs 154/87 mmHg, respectively).
13. American Diabetes Association. Standards of medical care for
Our blood pressure goal (135/85 mmHg for the majorpatients with diabetes mellitus. Diabetes Care 1997; 20: S5-S13 ity of patients) is actually lower than those goals. Thus, 14. Geiger H. Are angiotensin II receptor blockers superior to any potential class-specific differences that irbesartan angiotensin converting enzyme inhibitors with regard to their renoprotective effect ? Nephrol Dial Transplant 1997; 12: 640-642 or amlodipine may have on cardiovascular risk may
